Clinical trial NCT00255190 - References

Gastroesophageal Reflux Disease — Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Citation(s)

•   Dabholkar AH, Han C, Paris MM, Perez MC, Atkinson SN, Peura DA
  The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 20
•   Friedlander EA, Pallentino J, Miller SK, VanBeuge SS
  The evolution of proton pump inhibitors for the treatment of gastroesophageal reflux disease. J Am Acad Nurse Pract. 2010 Dec;22(12):674-83. doi: 10.1111/j.1745-7599.2010.00578.x. Epub 2010 Nov 24. Rev
•   Peura DA, Metz DC, Dabholkar AH, Paris MM, Yu P, Atkinson SN
  Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. Aliment Pharmacol Ther. 2009 Nov 15;30(10):1010-21

A Phase 3, Open-Label Study to Assess the Long-Term Safety of Dexlansoprazole MR (60 mg QD and 90 mg QD)

Details for clinical trial NCT00255190